Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-Resistant Prostatic Cancer”

194 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 194 results

Not applicableLooking for participantsNCT07463092
What this trial is testing

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Who this might be right for
Prostate CancerSarcopenia
University of Sao Paulo 34
Not applicableStudy completedNCT00853164
What this trial is testing

A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Who this might be right for
Prostate Cancer
Washington University School of Medicine 8
Large-scale testing (Phase 3)Ended earlyNCT03031821
What this trial is testing

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

Who this might be right for
Prostate CancerMetabolic Syndrome
Canadian Urologic Oncology Group 168
Early research (Phase 1)Ended earlyNCT05241613
What this trial is testing

AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc 28
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Testing effectiveness (Phase 2)Ended earlyNCT03577028
What this trial is testing

Study of HPN424 in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 104
Testing effectiveness (Phase 2)Study completedNCT01867333
What this trial is testing

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Ended earlyNCT01996696
What this trial is testing

Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

Who this might be right for
Prostatic Neoplasm
AHS Cancer Control Alberta 83
Testing effectiveness (Phase 2)Study completedNCT01942837
What this trial is testing

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 67
Very early researchStudy completedNCT02113657
What this trial is testing

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02429193
What this trial is testing

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

Who this might be right for
Castration-resistant Prostate Cancer
University Health Network, Toronto 16
Testing effectiveness (Phase 2)Study completedNCT00414388
What this trial is testing

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

Who this might be right for
Prostate Cancer
Oncology Specialists, S.C. 22
Early research (Phase 1)Ended earlyNCT04279561
What this trial is testing

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center 9
Large-scale testing (Phase 3)Active Not RecruitingNCT03748641
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC 765
Testing effectiveness (Phase 2)Looking for participantsNCT06457919
What this trial is testing

Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 50
Not applicableStudy completedNCT01383863
What this trial is testing

A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Ipsen 180
Early research (Phase 1)Looking for participantsNCT04104607
What this trial is testing

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Who this might be right for
Castration-Resistant Prostatic Cancer
University Hospital Tuebingen 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Early research (Phase 1)Study completedNCT02814669
What this trial is testing

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Who this might be right for
Castrate-Resistant Prostate Cancer
Hoffmann-La Roche 45
Load More Results